A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their tumoral specificity and because they are shared by many tumors. Antigenic peptide MEVDPIGHLY, which is encoded by MAGE-3 and is known to be presented by human leukocyte antigen (HLA)-B44, is currently being used in therapeutic vaccination trials. We report here that a cytolytic T lymphocyte (CTL) clone, which is restricted by HLA-B*1801, recognizes the same peptide and, importantly, lyzes HLA-B18 tumor cells expressing MAGE-3. These results imply that the use of peptide MEVDPIGHLY can now be extended to HLA-B18 patients. We also provide evidence that, under limiting amounts of protein MAGE-3, HLA B*1801 and B*4403 compete for binding to the peptide.
D017951:Antigen Presentation / Q000502:physiology*; D000951:Antigens, Neoplasm / Q000302:isolation & purification / Q000378:metabolism*; D001402:B-Lymphocytes / Q000378:metabolism / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism* / Q000821:virology; D002472:Cell Transformation, Viral; D002999:Clone Cells / Q000737:chemistry / Q000276:immunology / Q000821:virology; D003713:Dendritic Cells / Q000378:metabolism / Q000821:virology; D015235:HLA-B Antigens / Q000378:metabolism*; D059911:HLA-B18 Antigen; D059948:HLA-B44 Antigen; D004854:Herpesvirus 4, Human / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation; D009363:Neoplasm Proteins / Q000302:isolation & purification / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D015235:HLA-B Antigens; D059911:HLA-B18 Antigen; D059948:HLA-B44 Antigen; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins